 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|
Company Help
|
Business Customers:
|
Professional Services:
|
Download a Report:
|
|
|
|
|
|
|
|
|
| |
|
In fiscal year 2004/2005, P&G invested $1.8 billion or 3.5% of Net Outside Sales in research and development (R&D).
This ranks us as one of the top-20 largest R&D investors among U.S.-based companies, which include Pfizer, General Electric, Sony, Merck, 3M, DuPont and Hewlett-Packard. Among consumer products companies, our investment easily exceeds our leading competitors'. We also have more Ph.D.s working in labs around the world than the combined science and engineering faculty at Harvard, MIT and Berkeley. And P&G currently (fiscal year 2004/2005) has 27,000 granted patents globally. That's eight new patents each day, putting us on par with Intel, Motorola, Pfizer and Lucent.
It is clear from P&G's financial investment that top management is deeply committed to innovation and continued emphasis on superior products. Chairman of the Board and President and Chief Executive A.G. Lafley has said, "Innovation is our lifeblood — new ideas and new products that make consumers' lives better, build customers' sales and profits, and build P&G's market share, sales, profits and Total Shareholder Return." |
|
|
|
